The EU's CHMP has given Gilead Sciences Inc. the go-ahead for marketing of its new fixed-dose combination HIV treatment Odefsey (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg; R/F/TAF).
The product is fixed-dose combination of 200 mg of Gilead's emtricitabine, 25 mg of its tenofovir alafenamide with 25 mg...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
